Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

Jonathan L. Kaufman,Meletios A. Dimopoulos,Merav Leiba,James P. Morton,P. Joy Ho,Kihyun Kim,Philippe Moreau,Heather J. Sutherland,Shinsuke Iida,Jin Seok Kim,H. Miles Prince,Albert Oriol-Rocafiguera,Nizar J. Bahlis,Ajai Chari,Hervé Avet-Loiseau,Christopher Chiu,David Soong,Jon Ukropec,Ming Qi,Jesús F. San Miguel

Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based on cytogenetic risk.

2019

8038Background: High-risk cytogenetic abnormalities confer poor outcomes in MM patients (pts). In POLLUX, D-Rd demonstrated significant clinical benefit, including prolonged progression-free surviv...

Keywords:

Refractory Multiple Myeloma
Pathology
Lenalidomide
Dexamethasone
Subgroup analysis
Oncology
Daratumumab
Internal medicine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations